Meridian Bioscience Inc. Stock News

CINCINNATI, Jan. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 20

Meridian Bioscience Inc. (NASDAQ:VIVO) concluded the trading at $19.98 on Thursday, December 23 with a fall of -1.24% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $20.23 and 5Y monthly beta was reading 0.42 with its price kept floating in the … Meridian Bioscience Inc. (VIVO) Volatility Hits 4.16%: How An Investor Should Respond Read More »

Meridian Bioscience, Inc. (NASDAQ:VIVO) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 2,340,000 shares, a drop of 24.0% from the November 15th total of 3,080,000 shares. Based on an average trading volume of 386,300 shares, the short-interest ratio is currently 6.1 days. []

When screening the market for bargain opportunities, investors may want to look for stocks whose trailing 12-month and forward price-earnings to growth (PEG) ratios are at or below 1.5 as of Dec. 13,

In last trading session, Meridian Bioscience Inc. (NASDAQ:VIVO) saw 0.39 million shares changing hands with its beta currently measuring 0.42. Companys recent per share price level of $19.60 trading at -$0.16 or -0.81% at ring of the bell on the day assigns it a market valuation of $795.96M. That closing price of VIVOs stock is Meridian Bioscience Inc. (NASDAQ:VIVO) Share Price Recovers 13.27% From Its Lows, But Can It Maintain Its Rise? Read More »

State of Alaska Department of Revenue increased its stake in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 5.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,626 shares of the companys stock after acquiring an additional 1,640 shares during the []

During the last session, Meridian Bioscience Inc. (NASDAQ:VIVO)s traded shares were 0.86 million, with the beta value of the company hitting 0.42. At the end of the trading day, the stocks price was $19.67, reflecting an intraday loss of -0.91% or -$0.18. The 52-week high for the VIVO share is $30.65, that puts it down A Bull Market Continues To Unfold On Meridian Bioscience Inc. (NASDAQ: VIVO), As It Continued To Rise 5.24% In Year-To-Date Read More »

CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board

Meridian Bioscience, Inc. (NASDAQ:VIVO)s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $21.40, but opened at $20.70. Meridian Bioscience shares last traded at $20.01, with a volume of 1,177 shares traded. A number of brokerages recently issued reports on VIVO. HC Wainwright upped their price objective on []

Related Stocks: VIVO ,

Zacks Investment Research downgraded shares of Meridian Bioscience (NASDAQ:VIVO) from a hold rating to a sell rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and []

Goldman Sachs Group Inc. cut its holdings in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 42.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 216,361 shares of the companys stock after selling 159,765 shares during the quarter. Goldman Sachs Group Inc.s holdings in Meridian Bioscience were worth $4,799,000 as of its most recent []